New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 5, 2012
08:31 EDTRGRXRegeneRx receives notice of allownace from U.S. Patent Office for new indication
RegeneRx Biopharmaceuticals has received a Notice of Allowance of a U.S. patent for the use of Thymosin beta 4, certain fragments, isoforms, derivatives and analogues to treat patients with glaucoma and elevated intraocular pressure. Glaucoma refers to a group of eye conditions that lead to damage to the optic nerve. This nerve carries visual information from the eye to the brain. In most cases, damage to the optic nerve is due to increased pressure in the eye, known as intraocular pressure. Glaucoma is the second most common cause of blindness in the United States. The patent will expire in 2026.
News For RGRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 26, 2015
10:26 EDTRGRXRegeneRx receives Israeli acceptance notice for use of TB4
RegeneRx announced that it has received a patent acceptance notice from the Israeli patent office with claims for administering Thymosin beta 4 to prevent or reduce tissue damage caused by an increase in blood flow, as is often the case when cardiac vessels are opened after a blockage causing a heart attack or in similar circumstances when treating stroke victims.
March 25, 2015
08:56 EDTRGRXRegeneRx receives initial payment for RGN-259 U.S. license
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use